insights_auto
Zašto je 524494 pao 3,51%?
Istražite detaljnijechevron_right
524494:BOM
IPCA Laboratories Ltd
1.845,00 INR
arrow_downward
−3,51%(−67,20) 1D
16. lis, 15:30:00 GMT+5:30 · INR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 524494...
Otvori
1.913,95 INR
Najviša
1.913,95 INR
Najniža
1.812,60 INR
Trž. kap.
468,21 mlr.
Prosj. kol.
27,90 tis.
Količina
12,00 tis.
Dividenda
0,33 %
Kvartalna dividenda
1,50 INR
Datum nakon isplate dividende
7. kol 2026.
P/E omjer
35,74
52-tjed. najviša
2.039,30 INR
52-tjed. najniža
1.252,95 INR
EPS
51,63 INR
Dionice u optjecaju
126,35 mil.
Broj djelatnika
17 tis.
Otvori
1.913,95 INR
Najviša
1.913,95 INR
Najniža
1.812,60 INR
Trž. kap.
468,21 mlr.
Prosj. kol.
27,90 tis.
Količina
12,00 tis.
Dividenda
0,33 %
Kvartalna dividenda
1,50 INR
Datum nakon isplate dividende
7. kol 2026.
P/E omjer
35,74
52-tjed. najviša
2.039,30 INR
52-tjed. najniža
1.252,95 INR
EPS
51,63 INR
Dionice u optjecaju
126,35 mil.
Broj djelatnika
17 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Financije.hr
·
prije 1 dan
Wall Street pred otvaranjem: Rotacija iz tehnologije jača, Dow preuzima vodstvo
Yahoo Finance
·
prije 20 minuta
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
MarketBeat
·
prije 46 minuta
Turn Therapeutics (NASDAQ:TTRX) Cut to "Sell" at Wall Street Zen
MarketBeat
·
prije 56 minuta
Amgen (NASDAQ:AMGN) Upgraded at Wall Street Zen
Profil
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
IPCA Laboratories Ltd – informacije
Glavni izvršni direktor-
Zaposlenici17,2 tis.
Osnovano19. lis 1949.
Sjedište-
Sektor-
Web-lokacijaipca.com